Patents Assigned to TAKEDA VACCINES, INC.
  • Publication number: 20190194628
    Abstract: The present disclosure relates to methods of producing Enterovirus C, e.g., for poliomyelitis vaccine production. In some embodiments, the methods include adding polysorbate to the cell culture medium during or prior to inoculation with the virus and/or culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus C produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Applicants: Takeda Vaccines, Inc., Takeda Pharmaceutical Company Limited
    Inventors: Raman RAO, Tatsuki SATO, Kaori ODA, Kuniaki NAKAMURA, Takeshi NISHIHAMA
  • Publication number: 20190111124
    Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.
    Type: Application
    Filed: March 27, 2017
    Publication date: April 18, 2019
    Applicant: Takeda Vaccines, Inc.
    Inventors: Jill Ann Livengood, Timothy Duane Powell
  • Publication number: 20190106682
    Abstract: Embodiments herein relate to live, attenuated alphaviruses that are incapable of replicating in mosquito cells and of transmission by mosquito vectors. Other embodiments concern methods of generating live, attenuated alphaviruses, constructs thereof and uses of these live, attenuated alphaviruses in immunogenic compositions. Other embodiments relate to pharmaceutical compositions including the live, attenuated alphaviruses and methods for manufacturing these live, attenuated viruses. Yet other embodiments relate to uses of these compositions in kits for portable applications such as vaccines against alphavirus infection and methods thereof.
    Type: Application
    Filed: March 28, 2017
    Publication date: April 11, 2019
    Applicant: Takeda Vaccines, Inc.
    Inventors: Jill Ann Livengood, Timothy Duane Powell
  • Patent number: 10233429
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 19, 2019
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Patent number: 10172930
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 8, 2019
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 10167320
    Abstract: Methods of purifying virus-like particles (VLPs) that are substantially free of process contaminants and infectious agents. The methods incorporate, for example, low-pH treatment during harvest and/or inactivation by a solvent and/or detergent during VLP capture.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: January 1, 2019
    Assignee: Takeda Vaccines, Inc.
    Inventor: Ross Taylor
  • Patent number: 10137186
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Patent number: 10130696
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 20, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
  • Patent number: 10052374
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: August 21, 2018
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20180195048
    Abstract: The present disclosure relates to methods of producing Enterovirus A, e.g., for vaccine production, that include culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus A produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.
    Type: Application
    Filed: February 12, 2016
    Publication date: July 12, 2018
    Applicant: Takeda Vaccines, Inc.
    Inventor: Raman RAO
  • Publication number: 20180187165
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Application
    Filed: October 27, 2017
    Publication date: July 5, 2018
    Applicant: Takeda Vaccines, Inc.
    Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
  • Patent number: 10010600
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Patent number: 10010599
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Publication number: 20180125965
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. Thus, there is a need to develop vaccines and immunogenic compositions for treating and/or preventing hand, food, and mouth disease, particularly in children. In order to meet this need, the present disclosure provides vaccines and immunogenic compositions for treating and/or preventing hand, foot, and mouth disease that include antigens from at least one virus that causes hand, foot, and mouth disease in humans, such as EV71, CA6, and CA16.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 10, 2018
    Applicant: Takeda Vaccines, Inc.
    Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
  • Patent number: 9890362
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 13, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Patent number: 9878031
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Grant
    Filed: December 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Patent number: 9867876
    Abstract: The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 16, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas R. Foubert
  • Patent number: 9861691
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 9, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9834757
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: December 5, 2017
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Patent number: 9821049
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 21, 2017
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, Robert F. Bargatze, William Tino